 |
Partnering
PharmaGap seeks co-development and licensing partners for its novel Protein Kinase C modulators (peptides and small molecules). The Company is pursuing a strategy of partnering its compounds at the pre-clinical or early clinical trial stage.
Research Partners
PharmaGap is currently
collaborating with respected academic researchers to move the company's
pre-clinical lead drug (PhGα1) forward
towards human clinical trials.
Dr. Gary Schwartz at Memorial Sloan-Kettering Cancer Center in New York City, New York is studying PhGα1 for use in cancer as monotherapy and as combinatorial therapy with widely-used chemotherapeutic agents. |
|
Dr. Michael Adams at Queen’s University, Kingston, Ontario is assessing PhGα1's pharmacodynamic and pharmacokinetic properties. |
A non-confidential summary of PharmaGap’s lead drug program (PKC Inhibitor for use in Oncology) is available for review.
Please contact:
Simon Goulet
COO
613.991.5370
simon.goulet@pharmagap.com
